ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Permissions
Right arrowRequest Permissions
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (6)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Capelli, A.
Right arrow Articles by Donner, C. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Capelli, A.
Right arrow Articles by Donner, C. F.
Eur Respir J 2005; 25:701-707
Copyright ©ERS Journals Ltd 2005

CCR5 expression and CC chemokine levels in idiopathic pulmonary fibrosis

A. Capelli, A. Di Stefano, I. Gnemmi and C. F. Donner

Division of Pulmonary Disease, "Salvatore Maugeri" Foundation, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Scientific Institute of Veruno, Veruno, Italy

CORRESPONDENCE: A. Capelli, Divisione di Pneumologia, Fondazione S. Maugeri IRCCS, Istituto Scientifico di Veruno, Veruno (Novara), Italy. Fax: 39 0322884776. E-mail: acapelli@fsm.it

Keywords: Bronchoalveolar lavage, CC chemokine, CC chemokine receptor 5, idiopathic pulmonary fibrosis

Received: July 9, 2004
Accepted December 26, 2004


   ABSTRACT
TOP
 ABSTRACT
METHODS
 RESULTS
 DISCUSSION
 ACKNOWLEDGEMENTS
 REFERENCES
 
CC chemokines play an important role in the pathogenetic mechanisms of interstitial lung disease, while a downregulation of CC chemokine receptor (CCR)5 in the fibrotic stages of sarcoidosis has been observed.

To evaluate the involvement of CC chemokines and the expression of CCR5 in idiopathic pulmonary fibrosis (IPF) and, more specifically, in usual interstitial pneumonia, 35 subjects were studied. CC chemokine ligand (CCL)2, CCL3 and CCL4 levels were measured in the bronchoalveolar lavage fluid (BALF) of 18 nonsmoker control subjects and 17 patients affected by IPF. CCR5 expression was evaluated in alveolar macrophages and lymphocytes.

The BALF levels of all chemokines were significantly increased in IPF: median (range) CCL3 1.6 (1.0–11.1) versus 1.2 (0.0–3.8) pg·mL–1; CCL4 6.2 (1.3–96.0) versus 3.4 (0.3–6.8) pg·mL–1; and CCL2 60.1 (16.7–251.3) versus 4.6 (0.5–119.4) pg·mL–1. CCL2 levels correlated negatively with the carbon monoxide diffusing capacity of the lung (DL,CO) and arterial oxygen tension. CCR5 expression was significantly reduced in lymphocytes from IPF compared with controls.

The CC chemokines investigated are involved in the inflammatory mechanisms of idiopathic pulmonary fibrosis, and the results are in agreement with the hypothesis of a downregulation of the T-helper 1 immunological response in this disease.

Idiopathic pulmonary fibrosis (IPF) is a specific form of chronic fibrosing interstitial pneumonia limited to the lung, with the histopathological characteristics of usual interstitial pneumonia (UIP) on lung biopsy 1. The aetiology is unknown. The histological hallmark and chief diagnostic criterion is a heterogeneous appearance at low magnification, with alternating areas of normal lung, interstitial inflammation, fibrosis and honeycomb change 1.

Normal repair following lung injury results in the rapid restoration of tissue integrity and function. In contrast to normal repair, chronic inflammation in IPF promotes fibroproliferation and deposition of extracellular matrix, reflecting disregulated and exaggerated tissue repair. A salient feature of chronic inflammation is infiltration by leukocytes, and their recruitment requires intercellular communication between infiltrating leukocytes on the one hand, and the endothelium and resident stromal and parenchymal cells on the other. These events are mediated by the generation of early-response cytokines, such as interleukin (IL)-1 and tumour necrosis factor (TNF), the expression of cell-surface adhesion molecules, and the production of chemotactic molecules, such as chemokines 2.

Originally described as chemotactic factors, chemokines are now known to modulate cytokine production, adhesion molecule expression and mononuclear cell proliferation 3. In animal models of IPF induced by bleomycin, CC chemokines such as CC chemokine ligand (CCL)3 (macrophage inflammatory protein (MIP)-1{alpha}) and CCL2 (monocyte chemotactic protein-1) have been shown to play a critical role in the initiation and maintenance of pulmonary lesions and their angiogenesis 3.

No data are available on the role of CCL4 (MIP-1ß) in IPF, but an augmented production of CCL4 by peripheral blood mononuclear cells and increased serum concentrations of this chemokine, together with CCL2 and CCL3, have been observed in systemic sclerosis involving the lung 4.

The balance between two macrophage-derived CC chemokines, CCL3 and CCL4, could potentially be involved in sustaining inflammation and a chronic course in IPF. Both of these chemokines recognise CC chemokine receptor (CCR)5 as a cellular receptor in activated T-lymphocytes and alveolar macrophages 5. Stimulation of CCR5 induces an intracellular biochemical cascade, with increased production and release of IL-2 and interferon (IFN)-{gamma} 6.

In a recent study on pulmonary sarcoidosis, an increase of CCR5 expression was observed in lymphocytes and alveolar macrophages of patients affected by sarcoidosis, but with a downregulation in the advanced stage; an involvement of CCL4 from the earliest phases of the disease was also observed, with an involvement of CCL3 prevalently in the advanced fibrotic stages of sarcoidosis 7. To compare IPF with the advanced stage of sarcoidosis in the present study, the authors measured the levels of CCL3 and CCL4 in bronchoalveolar lavage (BAL) of patients affected by IPF and the expression of their receptor CCR5 in alveolar cells. The BAL fluid (BALF) concentrations of CCL2 and their correlations with the degree of functional impairment were also evaluated. Some results of this study have been previously reported in the form of an abstract 8.


   METHODS
TOP
 ABSTRACT
 METHODS
RESULTS
 DISCUSSION
 ACKNOWLEDGEMENTS
 REFERENCES
 
Study population
Eighteen healthy, nonsmoker historical controls, who presented also in a previous study by the current authors 7, and 17 patients affected by mild–moderate IPF were studied. IPF was diagnosed on the basis of clinical, functional, radiographic and histological criteria. According to the definition of IPF by the American Thoracic Society and European Respiratory Society international consensus statement, nine patients had histological evidence of UIP at biopsy obtained with thoracotomy or video-assisted thoracoscopy, and eight patients were diagnosed as IPF with transbronchial biopsy and BAL in the presence of all major and minor diagnostic criteria 1. Nine patients were nonsmokers and eight were ex-smokers (for ≥5 yrs). Treatment with steroid or nonsteroid anti-inflammatory drugs was stopped ≥3 months before inclusion in the study. None of the subjects had ever been prescribed cytotoxic or immunomodulatory drug therapy before inclusion.

Informed consent was obtained from each subject, and the protocol was approved by the Review Board of the Scientific Institute of Veruno, Veruno, Italy.

Pulmonary function tests
Pulmonary function testing included the measurement of forced expiratory volume in one second, forced vital capacity (6200 Autobox Pulmonary Function Laboratory; Sensormedics Corp., Yorba Linda, CA, USA) and carbon monoxide diffusing capacity of the lung (DL,CO), determined by the single-breath method (2200 Pulmonary Function Laboratory; Sensormedics Corp.).

Processing of bronchoalveolar lavages
BAL was performed as previously described 9. Briefly, three 50-mL boluses of 37°C pre-warmed sterile 0.9% saline were instilled in the right middle lobe and recovered by syringe with normal suction. Fluids were filtered through a monolayer of sterile gauze. Cytocentrifuge (Cytospin II; Shandon, London, UK) slides, prepared with native fluid, were stained with May-Grunwald Giemsa to determine the cell differentials. A total of 500 cells (without epithelial cells) per slide was examined at x1,000 magnification. The cytocentrifuge slides used for immunocytochemistry were fixed for 2 min with acetone and frozen at -80°C until analysis. BAL supernatants obtained after refrigerated (4°C) centrifugation were immediately stored at –80°C until analysis.

Immunocytochemistry
The expression of CCR5 in BAL cells was assessed by immunocytochemistry on frozen cytocentrifuge slides. The anti-CCR5 (MAB 181) was purchased from R&D Systems (Abington, UK). Monoclonal antibody binding was detected with the alkaline phosphatase anti-alkaline phosphatase method (APAAP kit system K670; Dako, Copenhagen, Denmark) and fast-red substrate.

Cytospin preparations of lipopolysaccharide-stimulated mononuclear cells were used as a positive control in each staining run. Negative control slides included cytospin preparations immunostained with mouse monoclonal immunoglobulin G2a (Dako).

Light-microscopic analysis of stained cells was performed at a magnification of x1,000 and a total of ≥250 cells (macrophages and lymphocytes) was examined and identified on the basis of morphological criteria.

Immunoassay
The levels of the chemokines in BALF, concentrated at least 10-fold with Centricon-3 concentrators (Amicon Inc., Beverly, MA, USA), were obtained with Quantikine CCL2, CCL3 and CCL4 ELISA kits (R&D Systems). This assay employs the quantitative sandwich-enzyme immunoassay technique. A monoclonal antibody specific for the chemokine is pre-coated onto a microtitre plate. The standard curves were prepared from 0 to 1,000 pg·mL–1. The lower limits of detection of the kits (manufacturer’s data) were 5.0, 6.0 and 4.0 pg·mL–1 for CCL2, CCL3 and CCL4, respectively. Standards and samples were run in duplicate. The results obtained were divided for the concentration value.

Statistical analysis
Demographic and functional data are reported as mean±SD; the other results are expressed as median (range). Differences between the two groups were assessed with an unpaired t-test for demographic and functional data, and Mann-Whitney U-tests for the other results. Spearman’s rank correlation coefficient was used to study correlations between chemokine concentrations and both pulmonary function tests and BAL cellular populations. Statistical significance was defined as p<0.05.


   RESULTS
TOP
 ABSTRACT
 METHODS
 RESULTS
DISCUSSION
 ACKNOWLEDGEMENTS
 REFERENCES
 
Functional data
Table 1Go shows the demographic and functional data of the study population. IPF patients were significantly older than control subjects. Restriction in pulmonary function tests and impaired gas exchange were observed in all IPF patients with a DL,CO of 52.2±13.9% and an arterial oxygen tension (Pa,O2) of 9.0±1.4 kPa, compared with 98.3±10.3% and 11.9±0.3 kPa in controls, respectively.


View this table:
[in this window]
[in a new window]
  		Table. 1— Demographic and functional data of the study population

 
Differential cell counts of BALF
The BAL number of total cells was slightly but significantly increased in IPF (200.3x103 cells·mL–1 versus 125.1x103 cells·mL–1; p<0.05) compared with controls, as shown in table 2Go. This increase consisted of both a per cent (p<0.0001) and absolute numerical (p<0.0001) increase of neutrophils and eosinophils. The median (range) number of macrophages in the BAL of control subjects and IPF patients was very similar (105.6 (46.4–234.1)x103 cells·mL–1 versus 119.0 (29.4–226.1)x103 cells·mL–1; nonsignificant).


View this table:
[in this window]
[in a new window]
  		Table. 2— Characteristics of bronchoalveolar lavage of the study population

 
BALF levels of CCL2, CCL3 and CCL4
All the chemokines evaluated were increased in the BALF of IPF patients. The increase of CCL3 (fig. 1Go) was slightly, but statistically, significant compared with controls (1.73 (1.05–11.07) versus 1.22 (0.0–3.84) pg·mL–1; p<0.03). More evident (fig. 2Go) was the difference between the two groups concerning the concentrations of CCL4 (7.03 (1.26–96.04) versus 3.10 (0.28–6.8) pg·mL–1; p<0.003). As expected, the levels of CCL2 in the BALF of patients affected by IPF were clearly increased, as shown in figure 3Go, compared with controls (68.65 (16.7–251.3) versus 4.56 (0.50–119.4) pg·mL–1; p<0.0001).



View larger version (7K):
[in this window]
[in a new window]
  		Fig. 1— Concentrations of CC chemokine ligand (CCL)3 in the bronchoalveolar lavage fluid of controls and idiopathic pulmonary fibrosis (IPF) patients. Horizontal bars represent median values. #: p<0.03.

 


View larger version (7K):
[in this window]
[in a new window]
  		Fig. 2— Concentrations of CC chemokine ligand (CCL)4 in the bronchoalveolar lavage fluid of controls and idiopathic pulmonary fibrosis (IPF) patients. Horizontal bars represent median values. #: p<0.003.

 


View larger version (9K):
[in this window]
[in a new window]
  		Fig. 3— Concentrations of CC chemokine ligand (CCL)2 in the bronchoalveolar lavage fluid of controls and idiopathic pulmonary fibrosis (IPF) patients. Horizontal bars represent median values. #: p<0.0001.

 
Relationship between functional impairment, BAL characteristics and concentrations of CCL2, CCL3 and CCL4
Since the two groups were significantly different, the current authors analysed the relationship between concentrations of the chemokines and both functional and cellular data within the IPF group alone. With control subjects excluded from the analysis, many statistically significant correlations disappeared. Nevertheless, the increase of CCL2 concentrations in the BALF of patients affected by IPF was correlated with Pa,O2 (p<0.003) and DL,CO (p<0.009), as shown in figure 4Go. No significant correlations were found comparing the concentrations of CCL4 and functional or cellular data. Conversely, as shown in figure 5Go, the levels of CCL3 in the BALF of IPF patients correlated significantly with both percentage and total number per mL of neutrophils ({rho} = 0.569, p<0.05, and {rho} = 0.608, p<0.02, respectively) and eosinophils ({rho} = 0.600, p<0.03, and {rho} = 0.675, p<0.02, respectively).



View larger version (11K):
[in this window]
[in a new window]
  		Fig. 4— Relationship of CC chemokine ligand (CCL)2 concentrations in the bronchoalveolar lavage fluid of idiopathic pulmonary fibrosis patients with a) carbon monoxide diffusing capacity of the lung (DL,CO; {rho} = –0.768; p = 0.0021) and b) arterial oxygen tension (Pa,O2; {rho} = –0.654; p = 0.009). kPa = 0.133xmmHg.

 


View larger version (11K):
[in this window]
[in a new window]
  		Fig. 5— Relationship between CC chemokine ligand (CCL)3 concentrations in the bronchoalveolar lavage fluid of idiopathic pulmonary fibrosis and percentage (a, c) and number (b, d) of neutrophils and eosinophils (a: {rho} = 0.569, p = 0.04; b: {rho} = 0.608, p = 0.015; c: {rho} = 0.600, p = 0.028; d: {rho} = 0.675, p = 0.015).

 
CCR5-positive cells in BALF
The alveolar macrophages of IPF patients and controls expressed the chemokine receptor CCR5 in a similar way, as shown in table 3Go. Conversely, the CCR5+ lymphocytes were significantly lower in IPF patients than controls, both in percentage and absolute number (p<0.002 and p<0.007, respectively).


View this table:
[in this window]
[in a new window]
  		Table. 3— T-cell subsets and CC chemokine receptor (CCR)5+ lymphocytes (Ly) and macrophages (Am) in bronchoalveolar lavage of the study population

 

   DISCUSSION
TOP
 ABSTRACT
 METHODS
 RESULTS
 DISCUSSION
ACKNOWLEDGEMENTS
 REFERENCES
 
The current findings demonstrate increased levels of three CC chemokines, CCL2, CCL3 and CCL4, in the BALF of patients affected by IPF, associated with a decreased expression of cellular receptor CCR5 in lymphocytes.

The pathogenesis of IPF or UIP is due to inflammation/injury to the alveolar-capillary wall basement membrane, leading to a loss of type-I epithelial and endothelial cells, proliferation of type-II cells, a loss of alveolar integrity, recruitment and proliferation of stromal cells, and deposition of extracellular matrix and end-stage fibrosis 10. McKee et al. 11 observed that hyaluronan fragments, glycosaminoglycan constituents of the extracellular matrix, are capable of activating macrophages and inducing the expression of genes whose functions are relevant to chronic inflammation, in particular, the chemokine gene family: CCL2, CCL3 and CCL4, cytokine responsive gene-2 and RANTES (regulated on activation, normal T-cell expressed and secreted) 11.

The involvement of CC chemokines in the inflammatory events of IPF has been observed in the increased levels of CCL2 and CCL3 in IPF, in the animal fluorescein isothiocyanate (FITC) and bleomycin models 3, 12 and in human studies 13. Using both FITC and bleomycin models in mice, Moore et al. 12 observed that animals with genetically modified CCR2–/– were protected from the development of pulmonary fibrosis compared with the wild-type CCR2+/+, even if, in both types of mice, CCL2 levels in BAL were increased.

In humans, Suga et al. 13 observed increased levels of CCL2 in the BAL and serum of patients affected by IPF, and demonstrated a relationship between serum levels of CCL2 and the clinical course of interstitial lung disease. The current findings confirm the increased levels of CCL2 in the BAL of patients affected by IPF compared with normal subjects, and reinforce the relationship observed by Suga et al. 13 between this chemokine and the clinical course of the disease, showing a significant correlation also with the degree of functional impairment and, thus, with the severity of the disease.

CCL2 and its receptor CCR2 are involved in fibrosis through the regulation of profibrotic fibroblast-derived cytokine generation and matrix deposition: fibroblasts isolated and cultured from fibrotic granuloma (T-helper (Th)2-type lesion) generated twice as many CCL2, as did similar numbers of fibroblasts from nonfibrotic granuloma (Th1-type lesion) or normal fibroblasts. In addition, stimulation of IL-4, a typical Th2 cytokine, also increases the number of normal fibroblasts expressing CCR2; in contrast, treatment with IFN-{gamma}, a Th1 cytokine, significantly decreases the number of CCR2-expressing normal and Th2-type fibroblasts 14. In addition, IFN-{gamma} can inhibit both fibroblast and chondrocyte collagen production in vitro, as well as decrease the expression of steady-state type-I and type-III procollagen mRNA; IFN-{gamma} is one of the major type-I cytokines that possesses profound regulatory activity for collagen deposition during chronic inflammation 15, 16.

In addition, since the activation of CCR5 induces an increased production of IL-2 and IFN-{gamma} 6, the downregulation of this receptor, which the current authors, for the first time, demonstrated in lymphocytes of IPF patients, could be correlated with a decrease in the levels of IFN-{gamma}.

Recently, whilst evaluating surgical biopsies, and isolating and culturing primary pulmonary fibroblast lines from UIP, Choi et al. 17 observed an increased expression of CCR5 in these latter cells, but did not evaluate alveolar macrophages and lymphocytes. Interestingly, in the same study, Choi et al. 17 also observed an increase of CCL7 levels in UIP, and reported that this chemokine could bind CCR5 with high affinity without eliciting a functional response and displacing CCR5 agonists. Hence, the presence of high levels of CCL7 could contribute to the reduced activity of CCR5 and, consequently, to the decreased production of IFN-{gamma}. In support of these data, in recent studies on sarcoidosis 7, 18, the current authors observed a downregulation of CCR5 expression in lymphocytes and macrophages between the first and third (fibrotic) stages, coupled with an increase of IL-4 concentrations and decreased levels of IFN-{gamma} in the BAL of patients with advanced disease compared with first and second stage. These data confirm the hypothesis that a persistent imbalance in the expression of Th2 versus Th1 cytokines in the lung acts as a mechanism for the progression of pulmonary fibrosis and that, in the advanced stages of sarcoidosis and pulmonary fibrosis, the type of inflammation is very similar, despite the fact that the initial disease is different. Less is known about the role of CCL3 and CCL4 in the inflammatory mechanism of IPF in humans.

An important role of CCL3 has been observed in the inflammatory process of fibrotic lung diseases and in the bleomycin-induced model of pulmonary fibrosis in mice 3, 19, in which treatment with anti-CCL3 antibody reduced the net lung hydroxyproline content by 49% compared with bleomycin-challenged mice treated with nonimmune serum 20. In a study on sarcoidosis, the current authors observed a different involvement of these CC chemokines during the evolution towards a fibrotic advanced stage 7. When evaluating groups of patients at different stages of sarcoidosis, an involvement of both these CC chemokines was observed: CCL4 from the earliest phases of the disease and CCL3 prevalently in the advanced fibrotic stages of sarcoidosis. In addition, a significant correlation was found between the levels of CCL3 in BAL and neutrophils 7.

In the present study, the authors confirmed increased levels of these two chemokines in the BAL of fibrotic patients and, as expected, an increase of the number and percentage of neutrophils, which positively correlate with CCL3 levels in BAL.

Bless et al. 21 observed in rats that CCL4 contributed significantly to the recruitment of neutrophils, and to lung production of TNF-{alpha}, which is secreted by hyperplastic type-II alveolar cells in pulmonary fibrosis and promotes DNA synthesis and proliferation of fibroblasts 22.

No correlation was found between CCL4 levels and the number or percentage of neutrophils. In fact, in humans, this chemokine is not involved in neutrophil recruitment 23.

Finally, viral infection, in particular, herpes virus chronic infection, is one of the hypothetic aetiologies of UIP 15, 22. Lillard et al. 24 observed recently that both CCL3 and CCL4 are not only involved in inflammation, but they also mediate mucosal and systemic adaptive immunity, enhancing the mucosal and serum humoral as well as cellular immune response against infectious diseases, particularly those of a viral origin. CCR5 is a coreceptor for entry of HIV-1 infection in cells, CCL7 is increased in UIP and prevents the binding of R5 strains of HIV 17, while CCL3 and CCL4 are potent inhibitors of M-tropic HIV infection 24, and both, as observed in the present study, are increased in UIP. All these observations could contribute to reinforce the hypothesis of viral involvement in the aetiology of UIP.

Therefore, the role and function of chemokines in the inflammation and immunity of pulmonary disease, and, in particular, in the pathogenesis of interstitial lung diseases, is far from being completely clarified. The present data, however, suggest a profibrotic role of CC chemokines in the progression of idiopathic pulmonary fibrosis and contribute, as understanding of the inflammatory mechanism underlying usual interstitial pneumonia/idiopathic pulmonary fibrosis increases, towards the development of possible approaches to challenge fibrogenesis as a means to combat this progressive and fatal disease.


   ACKNOWLEDGEMENTS
TOP
 ABSTRACT
 METHODS
 RESULTS
 DISCUSSION
 ACKNOWLEDGEMENTS
REFERENCES
 
The authors thank R. Allpress for her editorial assistance.


   REFERENCES
TOP
 ABSTRACT
 METHODS
 RESULTS
 DISCUSSION
 ACKNOWLEDGEMENTS
 REFERENCES
 

  1. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000;161:646–664.[Free Full Text]
  2. Streiter RM, Keane MP. Cytokine biology and pathogenesis of interstitial lung disease. In: King TE Jr, ed. Continuing Education Monograph series: New approaches to managing idiopathic pulmonary fibrosis. New York, American Thoracic Society, 2000; pp. 27–35.
  3. Smith RE, Strieter RM, Phan SH, Kunkel SL. C-C chemokine: novel mediators of the profibrotic inflammatory response to bleomycin challenge. Am J Respir Cell Mol Biol 1996;15:693–702.[Web of Science][Medline] [Order article via Infotrieve]
  4. Hasegawa M, Sato S, Takehara K. Augmented production of chemokines (monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory protein-1{alpha} (MIP-1{alpha}) and MIP-1ß) in patients with systemic sclerosis: MCP-1 and MIP-1{alpha} may be involved in the development of pulmonary fibrosis. Clin Exp Immunol 1999;117:159–165.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  5. Wu L, La Rosa G, Kassam N, et al. Interaction of chemokine receptor CCR5 with its ligands: multiple domains for HIV-1 gp 120 binding and a single domain for chemokine binding. J Exp Med 1997;186:1373–1381.[Abstract/Free Full Text]
  6. Loetscher P, Uguccioni M, Bordoli L, et al. CCR5 is characteristic of Th1 lymphocytes. Nature 1998;391:344–345.[Medline] [Order article via Infotrieve]
  7. Capelli A, Di Stefano A, Lusuardi M, Gnemmi I, Donner CF. Increased macrophage inflammatory protein-1{alpha} and macrophage inflammatory protein-1ß levels in bronchoalveolar lavage fluid of patients affected by different stage of pulmonary sarcoidosis. Am J Respir Crit Care Med 2002;165:236–241.[Abstract/Free Full Text]
  8. Capelli A, Di Stefano A, Lusuardi M, Gnemmi I, Donner CF. CCR5 expression and CC-chemokine levels in broncho-alveolar lavage (BAL) fluid of patients with idiopathic pulmonary fibrosis (IPF). Eur Respir J 2002;20: Suppl. 38 598s
  9. Capelli A, Lusuardi M, Carli S, Donner CF. Acid phosphatase (E.C. 3.1.3.2.) activity in alveolar macrophages from patients with active sarcoidosis. Chest 1991;99:545–550.
  10. Streiter RM. Inflammatory mechanisms are not a minor component of the pathogenesis of idiopathic fibrosis. Am J Respir Crit Care Med 2002;165:1205–1208.[Free Full Text]
  11. McKee CM, Penno MB, Cowman M, et al. Hyaluronan (HA) fragments induce chemokine gene expression in alveolar macrophages. The role of HA size and CD44. J Clin Invest 1996;98:2403–2413.[Web of Science][Medline] [Order article via Infotrieve]
  12. Moore BB, Paine R 3rd, Christensen PJ, et al. Protection from pulmonary fibrosis in the absence of CCR2 signaling. J Immunol 2001;167:4368–4377.[Abstract/Free Full Text]
  13. Suga M, Iyonaga K, Ichiyasu H, Saita N, Yamasaki H, Ando M. Clinical significance of MCP-1 levels in BALF and serum in patients with interstitial lung diseases. Eur Respir J 1999;14:376–382.[Abstract]
  14. Hogaboam CM, Bone-Larson CL, Lipinski S, et al. Differential monocyte chemoattractant protein-1 and chemokine receptor 2 expression by murine lung fibroblasts derived from Th1- and Th2-type pulmonary granuloma models. J Immunol 1999;163:2193–2201.[Abstract/Free Full Text]
  15. Streiter RM. Mechanism of pulmonary fibrosis. Conference summary. Chest 2001;120: Suppl. 1 77S–85S.[Free Full Text]
  16. Sampson PM, Rochester CL, Freundlich B, Elias JA. Cytokine regulation of human lung fibroblast hyaluronan (hyaluronic acid) production. Evidence for cytokine-regulated hyaluronan (hyaluronic acid) degradation and human lung fibroblast-derived hyaluronidase. J Clin Invest 1992;90:1492–1503.
  17. Choi ES, Jakubzick C, Carpenter KJ, et al. Enhanced monocyte chemoattractant protein-3/CC chemokine ligand-7 in usual interstitial pneumonia. Am J Respir Crit Care Med 2004;170:508–515.[Abstract/Free Full Text]
  18. Capelli A, Di Stefano A, Gnemmi I, Vecchio C, Donner CF. IFN-{gamma} and IL-4 levels in bronchoalveolar lavage of patient affected by different stages of sarcoidosis. Eur Respir J 2003;22: Suppl. 45 377S[CrossRef]
  19. Ziegenhagen MW, Schrum S, Zissel G, Zipfel PF, Schlaak M, Muller-Quernheim J. Increased expression of proinflammatory chemokines in bronchoalveolar lavage cells of patients with progressive idiopathic pulmonary sarcoidosis and sarcoidosis. J Investig Med 1998;46:223–231.[Web of Science][Medline] [Order article via Infotrieve]
  20. Smith RE, Strieter RM, Phan SH, et al. Production and function of murine macrophage inflammatory protein-1{alpha} bleomycin-induced lung injury. J Immunol 1994;153:4704–4712.[Abstract]
  21. Bless NM, Huber-Lang M, Guo R, et al. Role of CC chemokines (macrophages inflammatory protein-1ß, monocyte chemoattractant protein-1, RANTES) in acute lung injury in rats. J Immunol 2000;164:2650–2659.[Abstract/Free Full Text]
  22. White ES, Lazar MH, Thannickal VJ. Pathogenetic mechanisms in usual interstitial pneumonia/idiopathic pulmonary fibrosis. J Pathol 2003;201:343–354.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  23. Menten P, Wuyts A, Van Damme J. Macrophage inflammatory protein-1. Cytokine Growth Factor Rev 2002;13:455–481.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  24. Lillard JW Jr, Singh UP, Boyaka PN, Singh S, Taub DD, McGhee JR. MIP-1{alpha} and MIP-1ß differentially mediate mucosal and systemic adaptive immunity. Blood 2003;101:807–814.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 Am. J. Respir. Cell Mol. Bio.Home page
A.-M. Pulichino, I-M. Wang, A. Caron, J. Mortimer, A. Auger, Y. Boie, J. A. Elias, A. Kartono, L. Xu, J. Menetski, et al.
Identification of Transforming Growth Factor {beta}1-Driven Genetic Programs of Acute Lung Fibrosis
Am. J. Respir. Cell Mol. Biol., September 1, 2008; 39(3): 324 - 336.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
G. Trujillo, E. C. O'Connor, S. L. Kunkel, and C. M. Hogaboam
A Novel Mechanism for CCR4 in the Regulation of Macrophage Activation in Bleomycin-Induced Pulmonary Fibrosis
Am. J. Pathol., May 1, 2008; 172(5): 1209 - 1221.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
C. P. Baran, J. M. Opalek, S. McMaken, C. A. Newland, J. M. O'Brien Jr., M. G. Hunter, B. D. Bringardner, M. M. Monick, D. R. Brigstock, P. C. Stromberg, et al.
Important Roles for Macrophage Colony-stimulating Factor, CC Chemokine Ligand 2, and Mononuclear Phagocytes in the Pathogenesis of Pulmonary Fibrosis
Am. J. Respir. Crit. Care Med., July 1, 2007; 176(1): 78 - 89.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Permissions
Right arrowRequest Permissions
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (6)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Capelli, A.
Right arrow Articles by Donner, C. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Capelli, A.
Right arrow Articles by Donner, C. F.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS